The potential role of nitrate, a nitric oxide donor, in the prevention and treatment of diabetic osteoporosis.

IF 3.9 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Frontiers in Endocrinology Pub Date : 2025-06-12 eCollection Date: 2025-01-01 DOI:10.3389/fendo.2025.1480838
Sajad Jeddi, Khosrow Kashfi, Asghar Ghasemi
{"title":"The potential role of nitrate, a nitric oxide donor, in the prevention and treatment of diabetic osteoporosis.","authors":"Sajad Jeddi, Khosrow Kashfi, Asghar Ghasemi","doi":"10.3389/fendo.2025.1480838","DOIUrl":null,"url":null,"abstract":"<p><p>Approximately 28% of individuals with diabetes have osteoporosis. Diabetoporosis, which refers to the diabetes-related decrease in bone quality and quantity, increases the risk of osteoporotic fractures by 600-700% in individuals with type 1 diabetes (T1D) and by 38-70% in those with type 2 diabetes (T2D) compared to non-diabetic individuals. Decreased nitric oxide (NO) bioavailability contributes to diabetoporosis. This review summarizes the potential role of nitrate as a NO donor in preventing and treating diabetic osteoporosis. Evidence suggests that organic and inorganic nitrates have anti-osteoporotic effects in animal models of osteoporosis, as demonstrated by increasing bone mineral density (BMD, 3-42%) and bone weight (6-160%). Observational human studies indicate a lower fracture risk (6-17%) and a higher BMD (3-5%) following organic nitrate administration. Similar protective effects (7-74% reduction in fracture risk and 8-84% increase in BMD) have been observed with nitrate-rich diets. Randomized controlled trials have also shown that nitrate increases circulating bone formation markers; however, no effect on fracture risk has been reported, and increased BMD (8.8%) was reported only in one study. Nitrate converts to nitrite and then to NO (exogenous NO), increasing NO bioavailability in bone. In addition, nitrate increases the expression of endothelial NO synthase (eNOS), thereby increasing the endogenous NO in bone. Nitrate-derived NO promotes bone formation and reduces bone resorption via the NO/cyclic guanosine monophosphate (cGMP)/protein kinase G (PKG) signaling pathway. In addition to increasing NO availability, nitrate may enhance plasma insulin levels, reduce hyperglycemia, and improve insulin resistance in diabetes, further contributing to nitrates' anti-osteoporotic effects in diabetic bone. In conclusion, NO-based interventions such as nitrate may have a potential role in preventing and treating diabetoporosis.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1480838"},"PeriodicalIF":3.9000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12197922/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fendo.2025.1480838","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Approximately 28% of individuals with diabetes have osteoporosis. Diabetoporosis, which refers to the diabetes-related decrease in bone quality and quantity, increases the risk of osteoporotic fractures by 600-700% in individuals with type 1 diabetes (T1D) and by 38-70% in those with type 2 diabetes (T2D) compared to non-diabetic individuals. Decreased nitric oxide (NO) bioavailability contributes to diabetoporosis. This review summarizes the potential role of nitrate as a NO donor in preventing and treating diabetic osteoporosis. Evidence suggests that organic and inorganic nitrates have anti-osteoporotic effects in animal models of osteoporosis, as demonstrated by increasing bone mineral density (BMD, 3-42%) and bone weight (6-160%). Observational human studies indicate a lower fracture risk (6-17%) and a higher BMD (3-5%) following organic nitrate administration. Similar protective effects (7-74% reduction in fracture risk and 8-84% increase in BMD) have been observed with nitrate-rich diets. Randomized controlled trials have also shown that nitrate increases circulating bone formation markers; however, no effect on fracture risk has been reported, and increased BMD (8.8%) was reported only in one study. Nitrate converts to nitrite and then to NO (exogenous NO), increasing NO bioavailability in bone. In addition, nitrate increases the expression of endothelial NO synthase (eNOS), thereby increasing the endogenous NO in bone. Nitrate-derived NO promotes bone formation and reduces bone resorption via the NO/cyclic guanosine monophosphate (cGMP)/protein kinase G (PKG) signaling pathway. In addition to increasing NO availability, nitrate may enhance plasma insulin levels, reduce hyperglycemia, and improve insulin resistance in diabetes, further contributing to nitrates' anti-osteoporotic effects in diabetic bone. In conclusion, NO-based interventions such as nitrate may have a potential role in preventing and treating diabetoporosis.

一氧化氮供体硝酸盐在预防和治疗糖尿病骨质疏松症中的潜在作用。
大约28%的糖尿病患者患有骨质疏松症。糖尿病骨质疏松症是指与糖尿病相关的骨质质量和数量下降,与非糖尿病患者相比,1型糖尿病(T1D)患者的骨质疏松性骨折风险增加了600-700%,2型糖尿病(T2D)患者的骨质疏松性骨折风险增加了38-70%。一氧化氮(NO)生物利用度降低导致糖尿病。本文综述了硝酸盐作为一氧化氮供体在预防和治疗糖尿病性骨质疏松中的潜在作用。有证据表明,有机和无机硝酸盐在骨质疏松动物模型中具有抗骨质疏松作用,可以增加骨密度(BMD, 3-42%)和骨量(6-160%)。观察性人体研究表明,有机硝酸盐治疗可降低骨折风险(6-17%),提高骨密度(3-5%)。富含硝酸盐的饮食也有类似的保护作用(骨折风险降低7-74%,骨密度增加8-84%)。随机对照试验也表明,硝酸盐增加了循环骨形成标志物;然而,没有报道对骨折风险有影响,只有一项研究报道了骨密度增加(8.8%)。硝酸盐转化为亚硝酸盐,然后转化为NO(外源NO),增加NO在骨中的生物利用度。此外,硝酸盐增加了内皮NO合成酶(eNOS)的表达,从而增加了骨内的内源性NO。硝酸盐衍生的NO通过NO/环鸟苷单磷酸(cGMP)/蛋白激酶G (PKG)信号通路促进骨形成并减少骨吸收。除了增加一氧化氮的可用性外,硝酸盐还可能提高糖尿病患者血浆胰岛素水平,降低高血糖,改善胰岛素抵抗,从而进一步促进硝酸盐在糖尿病患者骨骼中的抗骨质疏松作用。综上所述,硝酸盐等以一氧化氮为基础的干预措施可能在预防和治疗糖尿病方面具有潜在作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Endocrinology
Frontiers in Endocrinology Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
5.70
自引率
9.60%
发文量
3023
审稿时长
14 weeks
期刊介绍: Frontiers in Endocrinology is a field journal of the "Frontiers in" journal series. In today’s world, endocrinology is becoming increasingly important as it underlies many of the challenges societies face - from obesity and diabetes to reproduction, population control and aging. Endocrinology covers a broad field from basic molecular and cellular communication through to clinical care and some of the most crucial public health issues. The journal, thus, welcomes outstanding contributions in any domain of endocrinology. Frontiers in Endocrinology publishes articles on the most outstanding discoveries across a wide research spectrum of Endocrinology. The mission of Frontiers in Endocrinology is to bring all relevant Endocrinology areas together on a single platform.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信